Filing Details
- Accession Number:
- 0001209191-17-004336
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-01-18 20:31:00
- Reporting Period:
- 2017-01-18
- Filing Date:
- 2017-01-18
- Accepted Time:
- 2017-01-18 20:31:00
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1175505 | Five Prime Therapeutics Inc | FPRX | Pharmaceutical Preparations (2834) | 260038620 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1423786 | Willard Francis Sarena | Two Corporate Drive South San Francisco CA 94080 | Chief Strategy Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-01-18 | 3,636 | $5.54 | 82,460 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-01-18 | 3,636 | $47.39 | 78,824 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2017-01-18 | 3,636 | $0.00 | 3,636 | $5.54 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
9,142 | 2022-07-15 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on October 27, 2015.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.04 to $47.61, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- This option is fully vested and immediately exercisable.